New mpox vaccine being tested in the UK
A new mpox vaccine is being tested in the UK, as the virus continues to spread in many parts of the world.
- Published: 14 March 2024
A new mpox vaccine is being tested in the UK, as the virus continues to spread in many parts of the world.
The first doses of the treatment have been given to patients at the NIHR Imperial CRF at Hammersmith Hospital
More than 8,000 babies took part in the HARMONIE trial, a partnership between Sanofi, AstraZeneca and the NIHR
A cost-effective malaria vaccine developed with support from the NIHR Oxford Biomedical Research Centre has been recommended for use by the World Health Organization (WHO).
The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox.
GP practices across the UK will play a vital role in a new Respiratory Syncytial Virus (RSV) study looking into the leading cause of infant hospitalisation.
Alternating doses of the Oxford/AstraZeneca and Pfizer vaccines generate robust immune responses against COVID-19, an NIHR supported study has found. The Com-COV study is led by the University of Oxford and run across eight NIHR sites in the UK.
The NIHR-funded and supported ChAdOx1 nCoV-2019 vaccine, developed by University of Oxford and AstraZeneca, is effective at preventing COVID-19 and offers a high level of protection, according to international research in more than 24,000 participants.